TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05806879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternity Napkin
Description: Use of maternity napkin with the following specifications (followed for 4.5 months)~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute.
Study: NCT05108922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aducanumab
Description: Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Study: NCT05625620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Pulse Current Stimulation
Description: Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Pulse Current Stimulation
Description: Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
Study: NCT04653532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Programme and Counselling
Description: A 6 month exercise and physical activity programme supported by an exercise specialist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Programme and Counselling
Description: A 6 month exercise and physical activity programme supported by an exercise specialist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Ignite and App
Description: A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
Study: NCT06547840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv18 IgE
Description: MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
Study: NCT06039267

Intervention type: OTHER
Intervention: Gut Microbiome Testing
Description: Stool microbiome testing using shotgun metagenomic sequencing

Intervention type: OTHER
Intervention: Gut Microbiome Testing
Description: Stool microbiome testing using shotgun metagenomic sequencing
Study: NCT04752605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Finnish ENGAGE together
Description: Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
Study: NCT05099666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Study: NCT06272877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluidotherapy
Description: Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation program
Description: The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
Study: NCT06689566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: After enrollment, there will be dose-escalation every 1 month with 3 doses of genistein (250 mg, 500 mg, and 750 mg BID orally) for complete 3 months. Afterwards, there will be 3 months washout period.
Study: NCT05190341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg oral
Description: 1 hour before HSG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30mg oral
Description: 1 hour before HSG
Study: NCT06687876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.
Study: NCT06692231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
Study: NCT06693622

Intervention type: BEHAVIORAL
Intervention: Patient survey
Description: To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.
Study: NCT06692413

Intervention type: OTHER
Intervention: Questionnaire
Description: Users who consent to the study will receive a questionnaire every 3 months
Study: NCT05598515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Participants will be asked to eat for only 8 hours out of 24 hours in a day.
Study: NCT06693375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal Magnetomotoric ultrasound (MMUS)
Description: MMUS examination of lymphnodes in rectum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles
Description: Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
Study: NCT06692751

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 2 tubes of 5 mL

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 2 tubes of 5 mL

Intervention type: PROCEDURE
Intervention: Ophthalmological examination
Description: angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A.

Intervention type: PROCEDURE
Intervention: Ophthalmological examination
Description: angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A.

Intervention type: OTHER
Intervention: angina severity questionnaire
Description: at inclusion, 3 months and 1 year Estimated filling time: 2 minutes

Intervention type: OTHER
Intervention: angina severity questionnaire
Description: at inclusion, 3 months and 1 year Estimated filling time: 2 minutes
Study: NCT06715488

Intervention type: DIAGNOSTIC_TEST
Intervention: AI assisted smartphone diagnosis
Description: Patients will examination and clinical photographs for convolutional networks to diagnose inflammatory arthritis
Study: NCT06747936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2281
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2281
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2282
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-2282
Description: PO, Once daily, 8weeks
Study: NCT06747221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systems Analysis and Improvement Approach (SAIA)
Description: SAIA is a 5-step implementation strategy that is repeated every 4-6 weeks for continuous quality improvement. It will be implemented by Kenyan public health workforce and frontline clinical care personnel to systematically identify and address bottlenecks to develop and implement solutions to delivery of HIV Testing Services during emergency department (ED) interactions.~Step 1: Understanding the cascade of ED patient flow from triage through care conclusion with focus on HTS opportunities. This will support identification of bottlenecks where patients are missed and provides data on potential increases in efficiency if misses are addressed.~Step 2: Use process mapping to identify modifiable bottlenecks.~Step 3: Define and implement workflow adaptations to mitigate modifiable bottlenecks.~Step 4: Monitor changes in performance.~Step 5: Repeat the analysis and improvement cycle (steps 1-4).
Study: NCT06746337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMAGINE
Description: IMAGINE is a digital group cognitive behavioral therapy intervention
Study: NCT06748066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-ACL development
Description: A meeting will be organized with all expert panel members to select relevant items. Before the meeting, experts will review a literature on ACL reconstruction return to sport processes. During round 1, the chairperson will ask panel members to suggest items to be included in the scale. Items with agreement from 5 or more members will be included in round 2. In round 2, redundant items will be identified and grouped, and new items will be added based on the literature and expert experience. Selected items will be randomly ordered to create a preliminary 6-level Likert scale (0 = strongly disagree, 5 = strongly agree).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-ACL scale validation
Description: The scale validation phase will involve 75 participants who have undergone ACL reconstruction within the past two years and are in the 'Return to Sport' process, with follow-up in the sports medicine department.~These participants will complete the final version of the SMART-ACL Scale in addition with the ACL-RSI scale and the IKDC Subjective Knee Form.~Validation will consist of testing face validity, construct validity, criterion validity (concurrent validity), and reliability, including internal consistency and test-retest reliability.
Study: NCT06746311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-101
Description: Single dose of HT-101 administered subcutaneously.
Study: NCT05899049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study: NCT06746311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-101
Description: Multiple dose of HT-101 administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, containing no active ingredient, administered subcutaneouly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, containing no active ingredient, administered subcutaneouly
Study: NCT05590949

Intervention type: OTHER
Intervention: Physical Evaluation
Description: Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry scans
Description: Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.

Intervention type: DIAGNOSTIC_TEST
Intervention: Trabecular Bone Score
Description: TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
Study: NCT05102006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007 Injection
Description: LBL-007 Injection; dose A or dose B; Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab is infused with a fixed dose of 3 mg/kg intravenously every three weeks
Study: NCT05899049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg administered Q6W via IV infusion
Study: NCT05601505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circulating tumor DNA
Description: This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
Study: NCT05872438

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vaginal, Oral and anal sampling
Description: The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
Study: NCT05270668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Tulisokibart administered at timepoints as directed by the protocol

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Companion diagnostic ( CDx)
Description: CDx+ or CDx-

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Companion diagnostic ( CDx)
Description: CDx+ or CDx-

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05149768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
Study: NCT06564402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Mental Rehearsal
Description: After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
Study: NCT04700124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (EV)
Description: 1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
Study: NCT06564402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Rehearsal
Description: After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
Study: NCT06638164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
Study: NCT04700124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RC + PLND
Description: Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
Study: NCT05899049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD via oral tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg administered QD via oral capsule
Study: NCT06292702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Burch colposuspension
Description: Peforming two stitches between the anterior vaginal wall and Cooper's ligament.
Study: NCT05792462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
Study: NCT06292702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Burch colposuspension
Description: Performing lateral tension for the anterior vaginal wall towards the intersection point of the arcus tendineus and the lower edge of the pubic bone then performing two stitches between the anterior vaginal wall and Cooper's ligament.
Study: NCT04700124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RC + PLND
Description: Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
Study: NCT06249867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 MG Extended Release Oral Tablet
Description: During the first two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
Study: NCT06373848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive 30 mg of Coq10
Description: A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.